Related content

Infliximab biosimilar CT‐P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : e325-e326

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Review of the Treatment of Psoriasis with Infliximab

By  

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 201-205

Bentham Science Publishers

Access to resources Recommend Favorite

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 70, Iss. 1, 2018-01 ,pp. : 60-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Psoriasis‐associated IgA nephropathy under infliximab therapy

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 3, 2015-03 ,pp. : e79-e80

John Wiley & Sons Inc

Access to resources Recommend Favorite